MedTrace Logo

Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery

NCT07180615 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 458

Last updated 2025-09-18

No results posted yet for this study

Summary

The goal of this clinical trial is to find out if a gut cleaning using Rifaximin works as well as the usual treatment with Neomycin and Metronidazole to prevent infections after colon surgery. The study includes adult patients who will have colon surgery.

The main question it aims to answer are:

-Does the Rifaximin treatment prevent surgical site infections as well as the Neomycin/Metronidazole treatment?

Other things the study will look at:

* How often infections happen, stratified on how deep they are, the type of surgery the patients got, or if bowel cleaning was done before surgery.
* How many people will die after surgery
* How long people stay in hospital

Participants will:

* Take either Rifaximin or Neomycin/Metronidazole one day before surgery to clean their gut
* Keep a diary until the surgery to record medication intake and any side effects
* Be contacted by phone 30 days after surgery to ask about their condition and any side effects,

Conditions

  • Surgical Site Infection
  • Colon Surgery
  • Surgical Site Infections

Interventions

DRUG

Rifaximin (Xifaxan)

Preoperative gut decolonization protocol based on oral Rifaximin 2x550mg 10 am and 10 pm on the day preceding the surgery

DRUG

Metronidazole

Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery

DRUG

Neomycin Sulfate

Preoperative gut decolonization protocols based on oral Neomycine 2x500mg and Metronidazole 2x500mg 10 am and 10pm on the day preceding the surgery

Sponsors & Collaborators

  • Universität Luzern

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-01-01
Completion
2029-06-30
FDA Drug
Yes

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180615 on ClinicalTrials.gov